SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge

 
• By Sten Stovall
  
Ovarian cancer
Lynparza tablets showed statistically significant, clinically meaningful improvement in PFS vs placebo • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D